Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
Senores Pharmaceuticals' shareholders approved all 8 postal ballot resolutions. Key approvals include enhancing inter-corporate loan/guarantee limits under Sections 185 and 186, and adjusting the utilization terms and timeline for IPO proceeds. These approvals provide increased financial and operational flexibility.
Aug 04 2026 17:51:33
Senores Pharmaceuticals Ltd - 544319 - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot
Senores Pharmaceuticals' shareholders approved all 8 postal ballot resolutions. Key approvals include enhancing inter-corporate loan/guarantee limits under Sections 185 and 186, and adjusting the utilization terms and timeline for IPO proceeds. These approvals provide increased financial and operational flexibility.
Aug 04 2026 17:48:44
Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On June 30, 2026
Senores Pharma filed its Q1 FY27 statement on IPO fund utilization, reporting an ongoing delay in deploying Rs.107 crore allocated for its Havix manufacturing facility. The company is seeking shareholder approval for variation in the object. Minor reallocations of unutilized funds were also reported across other objectives.
Jul 27 2026 17:40:58
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Senores Pharma released its Q1 FY27 IPO fund utilization report, indicating a Rs. 65.02 crore re-allocation of funds from the Atlanta sterile injections facility project to other subsidiary capital expenditure needs. Delays in the Atlanta project are attributed to geo-political issues, requiring shareholder approval for the revised plan and extended timeline to Q4 FY28.
Jul 27 2026 17:32:10
Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Senores Pharma reported robust Q1 FY27 results with consolidated revenue of Rs.180 crs, marking a 36% YoY growth. Net profit surged 56% to Rs.31 crs, alongside an 87% increase in EBITDA driven by margin expansion.
Jul 27 2026 15:47:23
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting
Senores Pharmaceuticals announced robust Q1 FY27 consolidated financial results with revenue growing 36% YoY to ₹180 cr and net profit up 56% YoY to ₹31 cr. The board also appointed Ms. Anjali Shah as Assistant VP-Finance (SMP) effective July 27, 2026.
Jul 27 2026 15:21:42
Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter Ended June 30, 2026 And To Transact Other Business Matters
Senores Pharmaceuticals announced its board will meet on July 27, 2026, to consider and approve the Q1 FY27 financial results. The meeting will also transact other business matters.
Jul 21 2026 15:58:18
Read More